The initiation of the second clinical trial in the INTerpath program represents rapid expansion in research for additional tumor types for individualized neoantigen therapy, V940 (mRNA-4157)
The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome
Cresemba is the only azole antifungal therapy approved for pediatric patients as young as one affected by these serious, potentially life-threatening infections
First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
Demonstrate significant bleed reduction in hemophilia A and B
Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment
There has been no loss or injury to human life
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
This product will be manufactured by Indoco Remedies at their manufacturing facility located at Goa
The agreement includes an upfront payment of US$15 million, regulatory and commercial milestones, and royalties
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
